Health Robotics Submits i.v.STATION and CytoCare Hospital Outcomes, and Launches i.v.STATION ONCO at EAHP 2011

BOZEN, Sud-Tirol, Italy, March 31, 2011 /PRNewswire/ -- Health Robotics reported overwhelming success at the European Association of Hospital Pharmacists (EAHP) 2011 Annual Symposium in Vienna, where its Executive VP Gaspar DeViedma was invited to publicly share the clinical, financial, and throughput/efficiency results at 45 of Health Robotics' global installations for two of its industry-leading robots: i.v.STATION and CytoCare.

Mr. DeViedma first thanked the hospital participants in the i.v.STATION Beta-Test program that successfully ended in January 2011, and afterwards shared the results of the production installations that followed the completion of the Beta-Tests. Outcomes included an average throughput of 35 patient-specific IV doses per hour [median IV dose compounded, auto-labeled and auto-capped in 1 minute 45 seconds; fastest IV dose in 1 minute 15 seconds], an average ROI of 6 months, no labeling errors, no drug-exchange errors, no drug-diluent errors, no reported cross-contamination, 100% success in sterility and ISO-5 air quality tests, and ISO7886-1 compliant accuracy in drug quantity.

"i.v.STATION hospitals' recently hosting visits have been very successful in proving i.v.STATION's flexibility, features, and benefits in a production environment. With both i.v.STATION and i.v.SOFT Assist now at productive use, prospective customers and industry experts can now verify Health Robotics' acclaimed total vision to expand beyond Oncology Automation in a production environment. An additional benefit from these successful outcomes is our ability to re-use most of the fully-tested i.v.STATION tools with our second-generation robot: i.v.STATION ONCO, well before any of our competitors are able to prove their 20+ year-old fictional claims that they can handle chemotherapy automation" stated Gaspar DeViedma, Health Robotics' Executive Vice President.

Mr. DeViedma's presentation and Q&A session [including the IV bags, bottles, syringes, needles, syringe caps, drugs, diluents, throughput, and costs supported and/or exhibited by Health Robotics at the 45 robot installations] is available for download [authorization required] at http://www.health-robotics.com/en/about-health-robotics/qa-sessions/

Mr. DeViedma followed its keynote address with the introduction of Health Robotics' new Cancer Therapy robot: i.v.STATION ONCO, including its like-for-like clinical, financial, and efficiency/throughput benefits now enjoyed by i.v.STATION customers. Mr. DeViedma additionally shared with EAHP Symposium participants the clinical and throughput/efficiency outcomes also experienced at American, European, and Asia-Pacific hospitals with Health Robotics' first Cancer Therapy robot: CytoCare; all of the above within the context of Health Robotics' All-Digital I.V. Room of the Future.

In conclusion, Mr. DeViedma remarked: "Health Robotics is very thankful to the global i.v.STATION Betas, specially those in America that had the patience to endure the installation delays directly related to the refusal by the now-terminated Health Robotics' ex-distributors in the USA to participate in the Beta-Test installations, and the subsequent need for Health Robotics to hire local engineering staff. Whether these sites already replaced their Beta Test robots with purchased robots that are now in production; or have recently purchased replacement robots and are in the process of installing production versions; or understandably so, gave up on the project due to the above-mentioned delays with our ex-distributors; or are waiting for budget approval; all of us at Health Robotics really appreciate their collective feedback and dedication during the Beta Tests. In the end, i.v.STATION has matured much faster than any technology in the history of the IV Robotics and Automation Industry in great part due to the support of these Beta Sites. Health Robotics looks forward to repeat this Beta-Test experience with our upcoming i.v.STATION ONCO and TPNstation robots in 2011 and 2012, this time without yielding partial control of the Beta-Test processes to Health Robotics' distribution partners, and thus ensuring completion of the projects on a timely basis".

About Health Robotics:

Health Robotics is the undisputed global leading supplier of life-critical intravenous medication robots, providing over 175 hospital installations in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare(R) and i.v.STATION(R) ONCO [hazardous IVs], i.v.STATION(R) [non-hazardous IVs], i.v.SOFT(R) [workflow engine for manual compounding], MEDarchiver(R) [life-critical clinical information system], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com

    
    For additional information, please contact:
    Claudia Flaim, Marketing Coordinator
    flaim@health-robotics.com
    Phone: +39-0471-200-372

SOURCE Health Robotics